Search

Your search keyword '"Gibbons, Don L."' showing total 25 results

Search Constraints

Start Over You searched for: Author "Gibbons, Don L." Remove constraint Author: "Gibbons, Don L." Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
25 results on '"Gibbons, Don L."'

Search Results

1. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non–small cell lung cancer

2. Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept

3. Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma

4. AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages

5. Archival single-cell genomics reveals persistent subclones during DCIS progression

7. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non–small cell lung cancer

8. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

10. Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology

13. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target

14. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC

15. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

16. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype

17. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC

18. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer

19. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC

Catalog

Books, media, physical & digital resources